Terminated PHASE3 INTERVENTIONAL 2-arm NCT00349752

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)

A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.

Sponsor: UCB Pharma

Conditions Crohn's Disease

Interventions Placebo certolizumab pegol 400 mg

Updated 11 times since 2017 Last updated: Jul 10, 2018 Started: Nov 30, 2006 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for subjects already recruited

Other terminated trials from UCB Pharma

See all terminations from UCB Pharma

Other Crohn's Disease trials with similar outcome

Browse all Crohn's Disease trials

This PHASE3 trial investigates Crohn's Disease and is currently terminated or withdrawn. UCB Pharma leads this study, which shows 11 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 6 earlier versions

Sep 2018 — Nov 2020 [monthly]

Terminated PHASE3
Jun 2018 — Sep 2018 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Annapolis, United States , Austin, United States , Birmingham, United States , Bloomington, United States , Bowling Green, United States , Burlington, United States , Calgary, Canada , Chapel Hill, United States , Charlotte, United States and 58 more locations